Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: August 14, 2022

Details for Patent: 7,504,509

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,504,509 protect, and when does it expire?

Patent 7,504,509 protects ZELBORAF and is included in one NDA.

This patent has fifteen patent family members in fourteen countries.

Summary for Patent: 7,504,509
Title:Compounds and methods for development of Ret modulators
Abstract: Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.
Inventor(s): Ibrahim; Prabha (Mountain View, CA), Artis; Dean Richard (Kensington, CA), Bremer; Ryan (Albany, CA), Habets; Gaston (Pleasant Hill, CA), Hurt; Clarence R. (San Ramon, CA), Mamo; Shumeye (Oakland, CA), Nespi; Marika (Berkeley, CA), Zhang; Chao (Moraga, CA), Zhang; Jiazhong (Oakland, CA), Zhu; Yong (Union City, CA), Zuckerman; Rebecca (Alameda, CA), Krupka; Heike (Hayward, CA), Kumar; Abhinav (Pleasant Hill, CA), West; Brian (San Francisco, CA)
Assignee: Plexxikon, Inc. (Berkley, CA)
Application Number:11/016,350
Patent Claim Types:
see list of patent claims
Compound; Composition; Device;

Drugs Protected by US Patent 7,504,509

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,504,509

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004308299 See Plans and Pricing
Canada 2550361 See Plans and Pricing
China 1925855 See Plans and Pricing
Cyprus 1118328 See Plans and Pricing
Denmark 1696920 See Plans and Pricing
European Patent Office 1696920 See Plans and Pricing
Spain 2527118 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.